课题基金 / 基金详情

项目摘要

项目成果

Dan H. Barouch的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 猴免疫缺陷病毒(SIV)或猴-人免疫缺陷病毒感染猕猴的研究 (SIV)是HIV-1感染的关键动物模型。非人灵长类(NHP)是复杂的、更高级的物种 这需要专门的基础设施和研究环境中经验丰富的工作人员。核心D(NHP核心)旨在 通过提供所有的专业知识、基础设施、试剂、人员、动物、 以及在猕猴体内进行复杂的体内研究的后勤保障。核心D将涉及领导力 来自贝丝以色列女执事医疗中心和Bioqual,并处于实现计划目标的有利地位。这个 核心D的目标是提供领导和技术专长,以确保以下方面的一致性和质量控制 动物选择、研究方案的执行、实验程序、样本获取和分配,以及 数据收集和分析。为了实现这一目标,我们提出了三个具体目标: 目的1.通过选择和提供恒河猴、提供特殊动物来支持这一P01计划 护理,并进行实验性疫苗研究 目标2.为血液和组织的接收、编目、加工、储存和分配提供设施 符合良好临床检验规范的样本 目标3.获得并保持拟议研究所需的所有监管批准
英文摘要
SUMMARY Infection of rhesus macaques with simian immunodeficiency virus (SIV) or simian-human immunodeficiency virus (SHIV) is a key animal model for HIV-1 infection. Nonhuman primates (NHP) are complex, higher order species that require specialized infrastructure and experienced staff in a research setting. Core D (NHP Core) aims to support this P01 program by providing all the expertise, infrastructure, reagents, personnel, animals, and logistics for the conduct of complex in vivo studies in rhesus macaques. Core D will involve leadership from Beth Israel Deaconess Medical Center and Bioqual and is well positioned to meet program objectives. The goal of Core D is to provide leadership and technical expertise to ensure consistency and quality control in animal selection, execution of study protocols, experimental procedures, sample acquisition and distribution, and data collection and analysis. To accomplish this goal, we propose three Specific Aims: Aim 1. To support this P01 program by selecting and providing rhesus macaques, providing exceptional animal care, and conducting experimental vaccine studies Aim 2. To provide facilities for the receipt, cataloging, processing, storage, and distribution of blood and tissue samples in compliance with Good Clinical Laboratory Practice Aim 3. To obtain and to maintain all required regulatory approvals for the proposed studies
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Multi-Omics Analysis of Broadly Neutralizing Antibodies and Therapeutic Vaccination
Administrative Core
Multi-Omics Correlates of Broadly Neutralizing Antibody Efficacy
CoVPN LOC Cross-Protocol Infrastructure Supplement for GY15 and GY16
海外基金